Frequently asked questions and answers : Coronavirus disease 2019 (COVID-19) and pregnancy by National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
Coronavirus Disease 2019 (COVID-19)
Frequently Asked Questions and Answers:
Coronavirus Disease 2019 (COVID-19) and Pregnancy
Pregnant women
Q: Are pregnant women more susceptible to infection, or at increased risk for severe illness, morbidity, or
mortality with COVID-19, compared with the general public?
A: We do not have information from published scientific reports about susceptibility of pregnant women to COVID-19.
Pregnant women experience immunologic and physiologic changes which might make them more susceptible to viral
respiratory infections, including COVID-19. Pregnant women also might be at risk for severe illness, morbidity, or
mortality compared to the general population as observed in cases of other related coronavirus infections [including
severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-
CoV)] and other viral respiratory infections, such as influenza, during pregnancy.
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Interim Guidance on breastfeeding for a mother confirmed or under investigation for COVID-19
More
Pregnant women should engage in usual preventive actions to avoid infection like washing hands often and avoiding
people who are sick.
Q: Are pregnant women with COVID-19 at increased risk for adverse pregnancy outcomes?
A: We do not have information on adverse pregnancy outcomes in pregnant women with COVID-19. Pregnancy loss,
including miscarriage and stillbirth, has been observed in cases of infection with other related coronaviruses [SARS-CoV
and MERS-CoV] during pregnancy. High fevers during the first trimester of pregnancy can increase the risk of certain birth
defects.
Q: Are pregnant healthcare personnel at increased risk for adverse outcomes if they care for patients with
COVID-19?
A: Pregnant healthcare personnel (HCP) should follow risk assessment and infection control guidelines for HCP exposed
to patients with suspected or confirmed COVID-19. Adherence to recommended infection prevention and control
practices is an important part of protecting all HCP in healthcare settings. Information on COVID-19 in pregnancy is very
limited; facilities may want to consider limiting exposure of pregnant HCP to patients with confirmed or suspected COVID-
19, especially during higher risk procedures (e.g., aerosol-generating procedures) if feasible based on staffing availability.
Transmission during pregnancy or during delivery
Q: Can pregnant women with COVID-19 pass the virus to their fetus or newborn (i.e. vertical transmission)?
A: The virus that causes COVID-19 is thought to spread mainly by close contact with an infected person through
respiratory droplets. Whether a pregnant woman with COVID-19 can transmit the virus that causes COVID-19 to her fetus
or neonate by other routes of vertical transmission (before, during, or after delivery) is still unknown. However, in limited
recent case series of infants born to mothers with COVID-19 published in the peer-reviewed literature, none of the infants
have tested positive for the virus that causes COVID-19. Additionally, virus was not detected in samples of amniotic fluid
or breastmilk.
Limited information is available about vertical transmission for other coronaviruses (MERS-CoV and SARS-CoV) but
vertical transmission has not been reported for these infections.
Infants
Q: Are infants born to mothers with COVID-19 during pregnancy at increased risk for adverse outcomes?
A: Based on limited case reports, adverse infant outcomes (e.g., preterm birth) have been reported among infants born to
mothers positive for COVID-19 during pregnancy. However, it is not clear that these outcomes were related to maternal
infection, and at this time the risk of adverse infant outcomes is not known. Given the limited data available related to
COVID-19 during pregnancy, knowledge of adverse outcomes from other respiratory viral infections may provide some
information. For example, other respiratory viral infections during pregnancy, such as influenza, have been associated
with adverse neonatal outcomes, including low birth weight and preterm birth. Additionally, having a cold or influenza
with high fever early in pregnancy may increase the risk of certain birth defects. Infants have been born preterm and/or
small for gestational age to mothers with other coronavirus infections, SARS-CoV and MERS-CoV, during pregnancy.
Q: Is there a risk that COVID-19 in a pregnant woman or neonate could have long-term effects on infant
health and development that may require clinical support beyond infancy?
A: At this time, there is no information on long-term health effects on infants either with COVID-19, or those exposed to
the virus that causes COVID-19 in utero. In general, prematurity and low birth weight are associated with adverse long-
term health effects.
Transmission through breast milk
Q: Is maternal illness with COVID-19 during lactation associated with potential risk to a breastfeeding
infant?
A: Human-to-human transmission by close contact with a person with confirmed COVID-19 has been reported and is
thought to occur mainly via respiratory droplets produced when a person with infection coughs or sneezes.
In limited case series reported to date, no evidence of virus has been found in the breast milk of women with COVID-19.
No information is available on the transmission of the virus that causes COVID-19 through breast milk (i.e., whether
infectious virus is present in the breast milk of an infected woman).
In limited reports of lactating women infected with SARS-CoV, virus has not been detected in breast milk; however,
antibodies against SARS-CoV were detected in at least one sample.
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